Phase 2 N=22 Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation
Scleritis · Orbital Disease
Primary: Reduction of Medications — 5; 4 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=8 Gevokizumab for Active Scleritis
Scleritis
Primary: Number of Participants With at Least a 2-step Reduction or Reduction to Grade 0 in Scleral Inflammation in the Study Eye (or Eyes), According to the National Eye…
Phase 2 N=5 Sirolimus Injections for Autoimmune Scleritis
Scleritis
Primary: Number of Participants Who Experience at Least 2-step Reduction or Reduction to Grade 0 of Scleral Inflammation in the Study Eye According to the National Eye Institute…
Phase 2 N=142 Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Scleroderma · Interstitial Lung Disease
Primary: Forced Vital Capacity (FVC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value — 66.52; 66.52; 66.22; 67.03 FVC %-pred — p=0.24
Phase 2 N=3 Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid
Ocular Cicatricial Pemphigoid
Primary: Number of Participants With no Evidence of Further Scarring (Fosters Staging) at 16 Weeks — 0 participants
N/A N=25 Ocular Effects of Scleral Lens Wear on Dry Eye Patients
Dry Eye
Primary: Mean Corneal Thickness — 570.54; 560.73 microns — p=0.25
Phase 4 N=14 Using Triamcinolone Acetonide to Reduce Pain After Scleral Buckle Surgery
Retinal Detachment
Primary: Post Operative Pain Day 1 — 2.2; 1.0 score on a scale
Phase 1 N=30 Sirolimus as Therapeutic Approach to Uveitis
Uveitis · Intermediate Uveitis · Posterior Uveitis
Primary: Number of Participants With at Least 2-step Decrease in Vitreous Haze (VH) — 4; 4 participants
Phase 2 N=12 Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment
Rheumatologic Disease
Primary: Flow Mediated Dilatation (FMD)-Diameter of Artery — 3.79; 3.78 mm
Phase 3 N=6 High Dose Cyclophosphamide for Treatment of Scleroderma
Scleroderma
Primary: Improvement in the Modified Rodnan Skin Score. — 46.75 percent improvement from baseline
Phase 2 N=19 Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma
SYSTEMIC SCLERODERMA
Primary: Time to Treatment Failure — 0; 8 participants
Phase 3 N=158 Scleroderma Lung Disease
Lung Diseases · Pulmonary Fibrosis · Systemic Scleroderma
Primary: Forced Vital Capacity — 66.6; 65.6 % of predicted
Phase 2 N=17 Riociguat in Scleroderma Associated Digital Ulcers
Scleroderma · Digital Ulcers
Primary: Change From Baseline to End of Double-blind Treatment (Week 16) in Digital Ulcer Net Burden — -1.22; -0.98 ulcers — p=0.70
Phase 3 N=75 Scleroderma: Cyclophosphamide or Transplantation
Scleroderma, Systemic · Sclerosis · Autoimmune Disease
Primary: Global Rank Composite Score (GRCS) (Month 54, ITT) — 17.0; -6.0 Sum of subject-pair comparison scores — p=0.013
Phase 3 N=38 Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis
Uveitis · Uveitis, Posterior · Uveitis, Anterior
Primary: Adverse Events — 27; 1 Participants
N/A N=22 Efficacy of Scleral Contact Lenses for Daily Wear for Regular and Irregular Refractive Errors Compared to Habitually Worn Scleral Lenses
Scleral Lens Wearers
Primary: The Primary Endpoint of the Study is the Overall Satisfaction and Desire to Continue Wearing the Study Lenses — 15; 2; 4 Participants
Phase 2 N=19 IL1-TRAP, Rilonacept, in Systemic Sclerosis
Scleroderma · Systemic Sclerosis · Diffuse Scleroderma
Primary: Change in 2- Gene Biomarker — -2.67; 0.42 2- gene biomarkers score
Phase 2 N=11 Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis
Uveitis · Intermediate Uveitis · Posterior Uveitis
Primary: Change in Intraocular Pressure (IOP) — -0.1 mm Hg
N/A N=45 Scleroderma ARFI Imaging of the Skin
Scleroderma
Primary: Mean Skin Stiffness — 2.68; 2.07; 2.23; 2.27 meters per second — p=0.005
Phase 2 N=31 Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious Uveitis
Uveitis
Primary: The Primary Outcome is the Time to Recurrence of Uveitis in Participants of Each Treatment Group, During or After Tapering of Oral Prednisone to a Dose of 7.5 mg/Day, or…
N/A N=9 Ocular Sarcoidosis Open Label Trial of ACTHAR Gel
Ocular Sarcoidosis · Panuveitis · Anterior Uveitis
Primary: Percentage of Patients With Clinically Significant Improvement in Visual Acuity — 3 Participants
Phase 2 N=22 Sildenafil for Treatment of Choroidal Ischemia
Choroidal Ischemia · Vitelliform Macular Dystrophy · Age-related Macular Degeneration
Primary: Change in Visual Acuity (Sildenafil Group) — 0.00; -0.03 logMAR
N/A N=20 A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma).
n Ulcer · Scleroderma, Systemic
Primary: New Digital Ulcers (DU) 4 Weeks Prior to Week 24 — 0.06 new digital ulcers
Phase 4 N=255 Multicenter Uveitis Steroid Treatment (MUST) Trial
Uveitis
Primary: Change in Best-corrected Visual Acuity (Change in the Numbers of Letters Read From a Standard ETDRS Eye Chart) From Baseline to 24 Months in Eyes With Uveitis — 6.0; 3.2…
Phase 2 N=7 Lucentis for Inflammatory Macular Edema Trial
Uveitis · Cytoid Macular Edema
Primary: The Mean Change at 3 Months in BSCVA From Baseline — 13 letters
Phase 2 N=18 Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia
Epistaxis · Hereditary Hemorrhagic Telangiectasia
Primary: Severityof Epistaxis — -0.4578; -1.4375 units on a scale
Phase 3 N=160 Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis
Uveitis · Uveitis, Posterior · Uveitis, Anterior
Primary: Number of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Best Corrected Visual Acuity at 24 Weeks — 45; 10 Participants — p=<0.001
Phase 2 N=9 Imatinib in Systemic Sclerosis
Scleroderma, Systemic
Primary: Percent Change in Modified Rodnan Skin Score at 6 Months Compared to Baseline — -32 percentage of change in MRSS — p=0.005
Phase 2 N=15 Eplerenone for Central Serous Chorioretinopathy
Central Serous Chorioretinopathy
Primary: Complete Resolution of Subretinal Fluid — 0 participants
Phase 2 N=80 Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca
Primary: Change From Baseline to Week 12 in Schirmer Test (ST) Score in Millimeters — 1.25; 3.81 Millimeters — p=0.027